Numerous antibody therapeutics—targeted to specific and other cancer cell surface markers—are adapted for pancreatic cancer treatment, including trastuzumab targeted to HER2 (human epidermal growth factor receptor 2, which is effective for breast cancer patients expressing the HER2 marker). This evidence concerns the gene ERBB2 and pancreatic neoplasm.